Chronic Inflammatory Demyelinating Polyneuropathy Market Factors, Industry Insights by Top Key Players, Forecast to 2023

Global Chronic Inflammatory Demyelinating Polyneuropathy Market size is set to the cross the mark of USD 3907.17 million with a Growing CAGR of CAGR of 6.2% during the forecast period, 2015-2023.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others), Industry Size, Growth, Technology, Share, Trends and Top Regions Forecast till 2023.

The increasing incidence of CIDP is a major concern in the medical sector, especially in developed countries. Several public and private organizations launched initiatives for R&D activities that produced positive results in the area of ​​CIDP.

Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/6947

The prevalence of autoimmune diseases has increased dramatically, paving the way for the growth of the global market for chronic inflammatory demyelinating polyneuropathy (CIDP). Remarkable results have been achieved through rigorous research and development efforts and clinical trials. Several new drugs are introduced following recent FDA approvals, which also spur growth of the global chronic inflammatory demyelinating polyneuropathy market. Other factors supporting the market growth comprise growing awareness of the disease and government initiatives on the same.

Some of the well-established market players in the global CIDP market includes

Pfizer Inc

Bio Products Laboratory Ltd.

Mitsubishi Tanabe Pharma Corporation

Baxter

Kedrion S.p.A

Octapharma

Shire

Momenta Pharmaceuticals

Grifols

CSL Behring

Teijin Pharma Limited

Industry Segmentation

The global market is diversified on the basis of the route of administration, treatment and diagnosis, and end-user.

The global chronic inflammatory demyelinating polyneuropathy market is divided into treatment and diagnoses. The treatment segment with the largest market share is further segmented into corticosteroids, plasma fermentation, intravenous immunoglobulin (IVIg), The global market is diversified on the basis of the route of administration, treatment, and diagnosis, and end-user.

The global chronic inflammatory demyelinating polyneuropathy market is divided into treatment and diagnoses. The treatment segment with the largest market share is further segmented into corticosteroids, plasma fermentation, physiotherapy, intravenous immunoglobulin (IVIg), plasmapheresis (plasma exchange), and others. The treatment segment also saw CAGR growth by 6.32% in the period due to growing demand for effective CIDP treatments. Of the different sub-segments, the IVIG sub-segment has achieved leadership status due to its preference for IVIg as a first-line treatment method for CIDP.

On the basis of the route of administration, the chronic inflammatory demyelinating polyneuropathy market is classified into intravenously and orally. Due to the strong preference for IVIG treatment that penetrates directly into the blood to respond more rapidly, the intravenous route segment is expected to gain the largest market share and highest annual growth over the forecast period. The intravenous solutions segment represents 85% of total market share, followed by oral and other treatments.

Based on end-users of the chronic inflammatory demyelination market for polyneuropathy is subdivided into specialized neurological clinics, research laboratories, hospitals, and academics, and others. Hospitals have gained a 49% share of the global market due to their wide presence and preference for hospitals. However, patients are progressively seeing the value of specialist clinics where they can better know their disease. As a result, the segment of specialized neurological clinics had the fastest CAGR growth of 6.49% during the period considered.

Browse Complete Premium Research Report at: https://www.marketresearchfuture.com/reports/chronic-inflammatory-demyelinating-polyneuropathy-market-6947

The main geographies covered in MRFR’s report include the Americas, Europe, Asia Pacific, and the Middle East & Africa. The global chronic inflammatory demyelinating polyneuropathy market has witnessed the highest presence in the Americas market. Possessing a share of 52% of the global market

5 Market Dynamics

5.1 Introduction

5.2 Drivers

5.2.1 Rising prevalence of autoimmune diseases

5.2.2 Increasing research and development related to plasma-derived medicines

5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

5.3 Restraints

5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment

5.3.2 High cost of the IVIG treatment

5.4 Opportunity

5.4.1 Advancements in the treatment

5.5 Clinical Trials Data

Ask for any Query Feel Free To contact at: https://www.marketresearchfuture.com/enquiry/6947

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com